P137 Main trial results of the EVAQ clinical study for the Q revascularization system in acute ischemic stroke

<h3>Introduction</h3> The Q Revascularization System is a novel thrombectomy device which aims to improve aspiration efficacy by increasing the system inner diameter. The larger diameter allows for greater impulse and acceleration of aspiration than traditional aspiration systems. <h3>Aim of Study</h3> Report the results of the EVAQ clinical study, <h3>Methods</h3> EVAQ is a prospective, single arm study with CEC and Core Lab assessed endpoints studying Q for the primary treatment of LVOs within 8hrs of symptom onset. Primary efficacy and safety endpoints are final mTICI2b-3 and sICH. Pre-specified secondary endpoints include revascularization after use of Q, first pass reperfusion and mRS0-2 at 90 days. <h3>Results</h3> The EVAQ study enrolled one hundred twenty-three subjects at 17 centers in France and the US from November 2020 to April 2023. Mean age was 68.3. Females were 52.8%. Mean NIHSS and ASPECTS were 15.8±5.9 and 8.1±1.5 respectively. Sites of large vessel occlusion treatment were Basilar 3.3%, ICA 13.9%, M1 MCA 64.2%, M2 MCA 17.1%, and other anterior location 1.6%. IV thrombolysis was administered in 55.5% of subjects. Onset to arterial puncture was 4.58 hours ±2.04. The primary outcome, final mTICI2b-3 by independent imaging core lab, was achieved in 93.9% of subjects. CEC adjudicated sICH per ECASS was 6.5%. Revascularization after the use of Q alone was 78.8% and first pass success was 56.7%. Time from groin puncture to successful revascularization was a mean of 38.2 minutes. <h3>Conclusion</h3> The novel Q Revascularization System is safe and effective for revascularization of Large Vessel Occlusions in acute ischemic stroke. <h3>Disclosure of Interest</h3> no.

Authors

Institutions

Publication Details

Journal
Abstracts
Published
2024-09-01
DOI
https://doi.org/10.1136/jnis-2024-esmint.173
Primary Topic
Neurological Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P137 Main trial results of the EVAQ clinical study for the Q revascularization system in acute ischemic stroke

Guillaume Bellanger, Osman Mir, Hubert Desal, Hamza A. Shaikh et al.
Abstracts
Neurological Disease Mechanisms and Treatments
article

P137 Main trial results of the EVAQ clinical study for the Q revascularization system in acute ischemic stroke

Guillaume Bellanger, Osman Mir, Hubert Desal, Hamza A. Shaikh, Lucas Elijovich, Alessandro Sgreccia, David S. Liebeskind, Jean Darcourt, Laurent Spelle, Brian Thomas Jankowitz, Michael Stiefel, Maxim Mokin, Florent Gariel, Morgane Laubacher, Clemens Maria Schirmer, Omer Eker, Benjamin Gory, Ashutosh P. Jadhav, Léon Ikka, Xavier Barreau, Charles Matouk, Gaultier Marnat, Silvia Pizzuto, Kunal V. Vakharia, Federico Di Maria, Liang Liao, Romain Bourcier, Christophe Cognard, Jazba Soomro, Adnan Siddiqui, Roberto Riva, Jason Davies, M Taqi, Pierre Louis Alexandre, Anne‐Christine Januel
article en

Abstract

<h3>Introduction</h3> The Q Revascularization System is a novel thrombectomy device which aims to improve aspiration efficacy by increasing the system inner diameter. The larger diameter allows for greater impulse and acceleration of aspiration than traditional aspiration systems. <h3>Aim of Study</h3> Report the results of the EVAQ clinical study, <h3>Methods</h3> EVAQ is a prospective, single arm study with CEC and Core Lab assessed endpoints studying Q for the primary treatment of LVOs within 8hrs of symptom onset. Primary efficacy and safety endpoints are final mTICI2b-3 and sICH. Pre-specified secondary endpoints include revascularization after use of Q, first pass reperfusion and mRS0-2 at 90 days. <h3>Results</h3> The EVAQ study enrolled one hundred twenty-three subjects at 17 centers in France and the US from November 2020 to April 2023. Mean age was 68.3. Females were 52.8%. Mean NIHSS and ASPECTS were 15.8±5.9 and 8.1±1.5 respectively. Sites of large vessel occlusion treatment were Basilar 3.3%, ICA 13.9%, M1 MCA 64.2%, M2 MCA 17.1%, and other anterior location 1.6%. IV thrombolysis was administered in 55.5% of subjects. Onset to arterial puncture was 4.58 hours ±2.04. The primary outcome, final mTICI2b-3 by independent imaging core lab, was achieved in 93.9% of subjects. CEC adjudicated sICH per ECASS was 6.5%. Revascularization after the use of Q alone was 78.8% and first pass success was 56.7%. Time from groin puncture to successful revascularization was a mean of 38.2 minutes. <h3>Conclusion</h3> The novel Q Revascularization System is safe and effective for revascularization of Large Vessel Occlusions in acute ischemic stroke. <h3>Disclosure of Interest</h3> no.

Abstracts
Amgen (United States) (US), Barrow Neurological Institute (US), Université de Bordeaux (FR), University of South Florida (US), UCLA Health (US), Piedmont Atlanta Hospital (US), Tampa General Hospital (US), Centre Hospitalier Universitaire de Nantes (FR), Yale University (US), Electronic Sensor Technology (United States) (US), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Centre d’Investigation Clinique Innovation Technologique de Nancy (FR), Semmes Murphey Foundation (US), Centre Hospitalier Le Vinatier (FR), Hôpital Purpan (FR), Jacobs Institute (US), Geisinger Wyoming Valley Medical Center (US), Piedmont HealthCare (US), Hôpital Foch (FR), Cooper University Health Care (US), John F. Kennedy Medical Center (US), Bicêtre Hospital (FR), University of Tampa (US)
Good health and well-being
Openalex Percentile: Top 84%
Neurological Disease Mechanisms and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.